Evidence map›Paper›PMID 32260109›Full record

ArticleCancers2020

Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage.

Riccardo Vago, Alessandro Ravelli, Arianna Bettiga, Silvana Casati, Giovanni Lavorgna, Fabio Benigni, Andrea Salonia, Francesco Montorsi, Marica Orioli, Pierangela Ciuffreda and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Endocannabinoids as potential biomarkers: It's all about pre-analytics.Journal of mass spectrometry and advances in the clinical lab · 2021
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Riccardo VagoUrological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, 20132 Milano, Italy.ORCID 0000-0002-3781-6770
Alessandro RavelliDipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Sezione di Tossicologia Forense, Università degli Studi di Milano, 20133 Milano, Italy.
Arianna BettigaUrological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, 20132 Milano, Italy.
Silvana CasatiDipartimento di Scienze Biomediche e Cliniche L. Sacco, Università degli Studi di Milano, 20157 Milano, Italy.ORCID 0000-0002-3865-0709
Giovanni LavorgnaUrological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, 20132 Milano, Italy.
Fabio BenigniUrological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, 20132 Milano, Italy.
Andrea SaloniaUrological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, 20132 Milano, Italy.ORCID 0000-0002-0595-7165
Francesco MontorsiUrological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, 20132 Milano, Italy.
Marica OrioliDipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Sezione di Tossicologia Forense, Università degli Studi di Milano, 20133 Milano, Italy.ORCID 0000-0003-1558-9551
Pierangela CiuffredaDipartimento di Scienze Biomediche e Cliniche L. Sacco, Università degli Studi di Milano, 20157 Milano, Italy.ORCID 0000-0003-2227-1373
Roberta OttriaDipartimento di Scienze Biomediche e Cliniche L. Sacco, Università degli Studi di Milano, 20157 Milano, Italy.ORCID 0000-0003-3379-0582
Vita-Salute San Raffaele University · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the involvement of the endocannabinoid system (ECS) in cancer onset and progression and the less studied connection between ECS and bladder cancer, here an evaluation of the ECS modifications associated with bladder cancer is reported. Urine samples were collected from healthy volunteers and patients with bladder cancer at different grades. Endocannabinoids (ECs) and N-acylethanolamides (NAEs) were quantified by HPLC-MS/MS and results normalized for creatinine content. An increase in the urine concentrations of four ECs and NAEs analyzed was observed with a statistically significant increase in the arachidonoylethanolamide (AEA) and stearoylethanoamide (SEA) associated with bladder cancer. Receiver operating characteristic curves built with AEA and SEA data allowed the selection of 160 pg/mL for SEA (area under the curve (AUC) = 0.91, Selectivity (SE) 94%, Specificity (SP) 45%) and 8 pg/mL for AEA (AUC = 0.85, SE 94%, SP 61%) as the best cut-off values. Moreover, data from bladder cancer samples at different grades were derived from The Cancer Genome Atlas, and the expressions of thirteen different components of the "endocannabinoidome" were analyzed. Statistical analysis highlights significant variations in the expression of three enzymes involved in EC and NAE turnover in bladder cancer.

Indexed as

biomarkersbladder cancerendocannabinoid quantificationendocannabinoid system

Identifiers

PMID32260109
PMCPMC7226386
OpenAlexW3014471879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.